Amylyx PharmaceuticalsAMLX
Recorded

Amylyx Pharmaceuticals Stifel 2026 Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration30 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

James CondulisAnalyst

All right, great. We'll get started with the next session. Happy to be here with Amylyx Pharmaceuticals. I have Co-CEO Josh Cohen and Chief Commercial Officer Dan Monahan. Thanks, guys, for coming. Congrats on all the success this year. Obviously, a super interesting time for you guys. Maybe Josh or Dan, if you want to just kind of kick it off with a brief kind of recap of the avexitide data and just sort of the setup from here in terms of catalysts and the regulatory path going forward.

Josh CohenCo-CEO

Sure. We're super excited. We had great data earlier this year. Met our pre-specified primary endpoint with a P-value of 0.000003 on our pre-specified primary outcome, which was the rate of level 2 and level 3 hypoglycemia in people living with PBH. To remind, level 2 is when your blood sugar goes below 54. That's often considered a level where neuroglycopenic symptoms or kind of severe neurological symptoms can begin. It was a composite outcome with level 3, which is when hypoglycemia has become so severe that you sort of require or it warrants independent rescue. We also met all of our secondary outcomes, had a favorable safety profile, so we're incredibly excited about those data. I think we had high expectations going in, but the data even exceeded our own expectations. Based on that data, we're now presenting at ObesityWeek this coming weekend.

Josh CohenCo-CEO

We're excited about that. I think we've already shared most of the headlines from the data, but I think there is a certain magic to getting all the figures and tables and whatnot out there as well. For the rest of the year, we're working towards submitting our NDA before year-end. We're on track to do that, which preps us for a commercial launch in 2027.

Josh CohenCo-CEO

It's been sort of an incredibly exciting, I'd say, sort of a milestone year for Amylyx, and I think we're set up for the next year as well.

James CondulisAnalyst

Yeah, definitely. Maybe just to level set on the data this weekend at ObesityWeek, just in terms of the breadth of data that we are going to get, is this the full sort of detailed data? Maybe it would just be helpful to understand if there is one or two key things you think is especially important for docs that maybe you have not kind of disclosed already.

James CondulisAnalyst

Yeah. Granted, you have been pretty disclosing already.

Josh CohenCo-CEO

Yeah, I think I would answer yes, this is the full data. All that being said, we like to continue to have presentations as time goes on. Wall Street does a good job, I think, of reading press releases. The medical community may not always get information when it comes out by press release or otherwise. So it is really important to be at medical conferences, speaking, sharing the information, doing one-on-ones with doctors, all those sorts of things. So, at ObesityWeek, we will present the double-blind placebo-controlled data. We will be excited to present the open-label extension data at a future time point. But again, I think as we have dug into this data, we just get more and more excited. I mean, it sort of goes with having such a strong P-value. You can sort of cut the data any which way, and you kind of get the same result.

Josh CohenCo-CEO

I mean, it is a very clear and strong effect that we are seeing here. I do not know that I would flag anything in specific. I think there is something cool about seeing the data in full with kind of tables and figures and everything like that.

James CondulisAnalyst

Yep. I think you guys have mentioned it's consistent with sort of the prior data, especially on the safety side as it relates to, I think the most common AEs were GI stuff, injection site reactions. Is that right that it's kind of consistent with the phase II is kind of where we should be thinking about?

Josh CohenCo-CEO

Yeah. Safety's been generally consistent with past trials. As well, tolerability was good. We had more than 90% of people complete the study. More than 90% of people enter the open-label extension. So people, good persistence as well in the study.

James CondulisAnalyst

Yeah. Makes sense. Great. So, looking ahead, you mentioned NDA end of this year. I think there's obviously, this is a sort of like established endpoint in terms of it's in the guidelines, very statistically significant. I think maybe one of the more important questions or questions people have as it relates to the regulatory dynamic is the label, and whether it's going to be Roux-en-Y specifically, more broad beyond just Roux-en-Y and kind of covering all PBH. Maybe just kind of help us understand what your latest kind of thinking there is and where people's heads should be at.

Josh CohenCo-CEO

Yeah. I think probably first and foremost, we don't think it's a particularly It won't change the commercial market all that much either way. We believe that approximately 120,000 of the 160,000 people living with PBH had Roux-en-Y gastric bypass. Whether the initial label kind of contemplates Roux-en-Y or contemplates more surgical types, it's maybe 120,000 versus 160,000, not that big of a difference. What I'd say is we do have data. Our phase IIb study was sort of a basket study.

Josh CohenCo-CEO

Yeah. Included multiple different surgical types.

Josh CohenCo-CEO

We recently published the Phase 2b, and when you look at the surgical types one by one, which is sort of done in the publication, the effect seems very similar across surgical types. We believe we have clinical data that also supports that there is not really differences here. It also sort of stands to reason medically. The body does not quite know why you conducted surgery on the gut, whether that was due to bariatric surgery, whether that was due to cancer, whether that was due to other reasons why you might do surgery on the gut. At the end of the day, you are getting the same sort of fast nutrient flow, the same GLP-1 spike, the same hypoglycemia. So we believe there is a good medical argument that these should all be treated the same.

Josh CohenCo-CEO

Of course, FDA may accept those arguments, they may not. If they do not, I think launching into a 120,000 market is also excellent.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day